Latest Medivir Ser B Sek5 (MVRBF) Headlines M
Post# of 3
Posted On: 03/10/2014 5:40:11 PM
Latest Medivir Ser B Sek5 (MVRBF) Headlines
Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented
Business Wire - Tue Mar 04, 11:30AM CST
Regulatory News:
Medivir reports profit in 2013
M2 - Mon Feb 24, 6:37AM CST
Swedish medical research company Medivir AB (STO:MVIRB.ST) reported today profit after tax of SEK16m, or SEK 0.51 per share, for the year 2013, from 1 January 2013 to 31 December 2013.
Swedish Pharmaceutical Company Medivir AB Chooses Certara's D360 as Its Global Drug Discovery Platform
Business Wire - Mon Jan 27, 7:00AM CST
Certara(TM), a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Medivir AB, a Swedish pharmaceutical company that focuses on infectious diseases including hepatitis C, has selected D360 as its global drug discovery platform. Certara's D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data. Medivir will use D360 to deliver research data and analytic tools to its discovery chemists and biologists in Stockholm, Sweden, and Cambridge, UK. The information will be sourced from its existing repository of chemical structure and biological assay data.
Medivir: Interim results (SVR4) from a phase II all-oral combination study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C
Business Wire - Mon Jan 13, 6:22AM CST
Regulatory News:
Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir
GlobeNewswire - Mon Jan 13, 6:00AM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from the Company's ongoing phase II 12-week HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir (IDX719), Idenix's once-daily pan-genotypic NS5A inhibitor, and simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, plus ribavirin. The combination regimen was well-tolerated in the study. In the treatment-naïve, non-cirrhotic, genotype 1b or 4 HCV-infected patients receiving 50 mg of samatasvir and 150 mg of simeprevir plus ribavirin, 85 percent (n=17/20) remained undetectable for HCV RNA four weeks after completing therapy (SVR4). The 50 mg dose of samatasvir is the selected dose in the ongoing 3-DAA HELIX-2 clinical trial. The HELIX-1 study results are expected to be presented at a scientific meeting in 2014.
Medivir: An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated
Business Wire - Thu Dec 12, 1:55AM CST
Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.
Medivir's Simeprevir now available for Hepatitis C patients in Japan, US and Canada
M2 - Tue Dec 10, 9:57AM CST
Medivir AB (STO:MVIRB.ST), an emerging research-based pharmaceutical company focused on infectious diseases, announced today that, based on the recent approvals in Japan, Canada and US, simeprevir is now available in all three markets.
Medivir: Simeprevir is now available for Hepatitis C patients in Japan, USA and Canada
Business Wire - Tue Dec 10, 1:47AM CST
Regulatory News:
Medivir: HELIX-2, a Phase II All-Oral Combination Study of Simeprevir, TMC647055 and Samatasvir (IDX719) for the Treatment of Hepatitis C Has Been Initiated
Business Wire - Mon Dec 02, 6:29AM CST
Regulatory News:
Idenix Pharmaceuticals Announces Initiation of Enrollment in a Phase II All-Oral Combination Study of Samatasvir (IDX719), Simeprevir, and TMC647055 for the Treatment of Hepatitis C Virus (HCV) Infection
GlobeNewswire - Mon Dec 02, 6:00AM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the initiation of patient enrollment in the phase II HELIX-2 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, simeprevir, a once-daily NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, and TMC647055, a once-daily NS5B non-nucleoside polymerase inhibitor boosted with low-dose ritonavir developed by Janssen.
Medivir announces approval of Simeprevir by US FDA as a new treatment for Hepatitis C
M2 - Wed Nov 27, 9:18AM CST
Medivir AB (OMX:MVIR), a research-based pharmaceutical company, announced on Saturday the approval by the US and Drug Administration (FDA) of simeprevir for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naive or who have failed previous interferon therapy (pegylated or non-pegylated) with ribavirin.
Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented
Business Wire - Tue Mar 04, 11:30AM CST
Regulatory News:
Medivir reports profit in 2013
M2 - Mon Feb 24, 6:37AM CST
Swedish medical research company Medivir AB (STO:MVIRB.ST) reported today profit after tax of SEK16m, or SEK 0.51 per share, for the year 2013, from 1 January 2013 to 31 December 2013.
Swedish Pharmaceutical Company Medivir AB Chooses Certara's D360 as Its Global Drug Discovery Platform
Business Wire - Mon Jan 27, 7:00AM CST
Certara(TM), a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Medivir AB, a Swedish pharmaceutical company that focuses on infectious diseases including hepatitis C, has selected D360 as its global drug discovery platform. Certara's D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data. Medivir will use D360 to deliver research data and analytic tools to its discovery chemists and biologists in Stockholm, Sweden, and Cambridge, UK. The information will be sourced from its existing repository of chemical structure and biological assay data.
Medivir: Interim results (SVR4) from a phase II all-oral combination study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C
Business Wire - Mon Jan 13, 6:22AM CST
Regulatory News:
Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir
GlobeNewswire - Mon Jan 13, 6:00AM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from the Company's ongoing phase II 12-week HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir (IDX719), Idenix's once-daily pan-genotypic NS5A inhibitor, and simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, plus ribavirin. The combination regimen was well-tolerated in the study. In the treatment-naïve, non-cirrhotic, genotype 1b or 4 HCV-infected patients receiving 50 mg of samatasvir and 150 mg of simeprevir plus ribavirin, 85 percent (n=17/20) remained undetectable for HCV RNA four weeks after completing therapy (SVR4). The 50 mg dose of samatasvir is the selected dose in the ongoing 3-DAA HELIX-2 clinical trial. The HELIX-1 study results are expected to be presented at a scientific meeting in 2014.
Medivir: An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated
Business Wire - Thu Dec 12, 1:55AM CST
Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.
Medivir's Simeprevir now available for Hepatitis C patients in Japan, US and Canada
M2 - Tue Dec 10, 9:57AM CST
Medivir AB (STO:MVIRB.ST), an emerging research-based pharmaceutical company focused on infectious diseases, announced today that, based on the recent approvals in Japan, Canada and US, simeprevir is now available in all three markets.
Medivir: Simeprevir is now available for Hepatitis C patients in Japan, USA and Canada
Business Wire - Tue Dec 10, 1:47AM CST
Regulatory News:
Medivir: HELIX-2, a Phase II All-Oral Combination Study of Simeprevir, TMC647055 and Samatasvir (IDX719) for the Treatment of Hepatitis C Has Been Initiated
Business Wire - Mon Dec 02, 6:29AM CST
Regulatory News:
Idenix Pharmaceuticals Announces Initiation of Enrollment in a Phase II All-Oral Combination Study of Samatasvir (IDX719), Simeprevir, and TMC647055 for the Treatment of Hepatitis C Virus (HCV) Infection
GlobeNewswire - Mon Dec 02, 6:00AM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the initiation of patient enrollment in the phase II HELIX-2 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, simeprevir, a once-daily NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, and TMC647055, a once-daily NS5B non-nucleoside polymerase inhibitor boosted with low-dose ritonavir developed by Janssen.
Medivir announces approval of Simeprevir by US FDA as a new treatment for Hepatitis C
M2 - Wed Nov 27, 9:18AM CST
Medivir AB (OMX:MVIR), a research-based pharmaceutical company, announced on Saturday the approval by the US and Drug Administration (FDA) of simeprevir for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naive or who have failed previous interferon therapy (pegylated or non-pegylated) with ribavirin.
(0)
(0)